FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance.
about
Microbial Biotransformation to Obtain New AntifungalsMechanisms of Candida biofilm drug resistanceGlobal analysis of the evolution and mechanism of echinocandin resistance in Candida glabrataEchinocandin resistance: an emerging clinical problem?Epidemiology and Risk Factors for Echinocandin Nonsusceptible Candida glabrata Bloodstream Infections: Data From a Large Multisite Population-Based Candidemia Surveillance Program, 2008-2014Breakthrough invasive Candida glabrata in patients on micafungin: a novel FKS gene conversion correlated with sequential elevation of MIC.Role of FKS Mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance.Regulatory circuitry governing fungal development, drug resistance, and disease.Species identification and antifungal susceptibility testing of Candida bloodstream isolates from population-based surveillance studies in two U.S. cities from 2008 to 2011.Elucidating drug resistance in human fungal pathogens.Comparative evaluation of a new commercial colorimetric microdilution assay (SensiQuattro Candida EU) with MIC test strip and EUCAST broth microdilution methods for susceptibility testing of invasive Candida isolates.Candida glabrata mutants demonstrating paradoxical reduced caspofungin susceptibility but increased micafungin susceptibilityFrequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata.Innate inflammatory response and immunopharmacologic activity of micafungin, caspofungin, and voriconazole against wild-type and FKS mutant Candida glabrata isolates.Recurrent episodes of candidemia due to Candida glabrata with a mutation in hot spot 1 of the FKS2 gene developed after prolonged therapy with caspofunginProgress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata.Invasive candidiasis in Pakistan: clinical characteristics, species distribution and antifungal susceptibility.CRS-MIS in Candida glabrata: sphingolipids modulate echinocandin-Fks interaction.Optimizing Echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without fks mutations.Two echinocandin-resistant Candida glabrata FKS mutants from South AfricaIn Vitro Activities of Six Antifungal Drugs Against Candida glabrata Isolates: An Emerging Pathogen.Sequence-identification of Candida species isolated from candidemia.Recurrent episodes of Candidemia due to Candida glabrata, Candida tropicalis and Candida albicans with acquired echinocandin resistance.Fluconazole and Echinocandin Resistance of Candida glabrata Correlates Better with Antifungal Drug Exposure Rather than with MSH2 Mutator Genotype in a French Cohort of Patients Harboring Low Rates of Resistance.Multicenter study of anidulafungin and micafungin MIC distributions and epidemiological cutoff values for eight Candida species and the CLSI M27-A3 broth microdilution method.Current perspectives on echinocandin class drugs.Development of a Luminex-based multiplex assay for detection of mutations conferring resistance to Echinocandins in Candida glabrata.Anidulafungin: when and how? The clinician's view.Molecular fingerprints to identify Candida species.Consensus guidelines for the treatment of yeast infections in the haematology, oncology and intensive care setting, 2014.Nosocomial Candidiasis: Antifungal Stewardship and the Importance of Rapid Diagnosis.Potential Use of MALDI-ToF Mass Spectrometry for Rapid Detection of Antifungal Resistance in the Human Pathogen Candida glabrataEchinocandin resistance and population structure of invasive Candida glabrata isolates from two university hospitals in Germany and Austria.Assessment of caspofungin susceptibility of Candida glabrata by the Etest®, CLSI, and EUCAST methods, and detection of FKS1 and FKS2 mutations.Echinocandins in antifungal pharmacotherapy.Rapid Detection of FKS-Associated Echinocandin Resistance in Candida glabrataBreakthrough candidemia due to multidrug-resistant Candida glabrata during prophylaxis with a low dose of micafungin.Caspofungin for the treatment of immunocompromised and severely ill children and neonates with invasive fungal infectionsIn Vitro Exposure to Increasing Micafungin Concentrations Easily Promotes Echinocandin Resistance in Candida glabrata Isolates.
P2860
Q26770689-3919560C-E2C7-46B5-AC61-C2BD13F9626CQ26827521-D747D710-BF40-4F67-8402-5B41E0BE9835Q28483785-112850FC-5CC6-4235-888D-AF24294A24F7Q28544739-2186FE72-0F41-4C65-9A83-1711454A612DQ31032549-0AB48409-8330-46B1-B53F-C9E2A289746CQ33900103-D216ED41-1C5F-481F-83F2-9A9D484DB7A0Q34058099-7ACFD309-1439-47A2-98CF-F18F9EE6D390Q34190284-754BEBEA-F523-4741-B53D-2D2E283B7A4EQ34372192-E9EB72FC-8A06-4D19-80A9-D48CFADB0E16Q34419351-E6128748-69DE-425F-9965-D1DB6C10AEECQ34916656-26AEC229-A01B-48A0-B704-F966228E0C20Q35139474-42928ED3-091C-4E6F-8848-7CF042D16082Q35867789-50BF402E-D76C-4477-9C44-327805B56934Q35960887-9454896C-E6B1-4F16-A1E7-632280C43AB1Q36018829-88DDDFBC-9B5E-4260-B658-0A6FD951312EQ36172242-55AEA660-1142-4A38-B39D-45C77306BB83Q36172500-A00AB5C8-9C24-4D54-800F-734BCC2434A3Q36237993-28DD57AC-F883-4696-A59E-22507DE0C54CQ36322437-B51D8E5C-AF2C-4523-AE03-2F512E0BD5E8Q36364100-9ED8AC10-CF0D-483F-98F6-F16613201587Q36740049-C62EDBDA-2C7A-462B-B009-DE75247F074EQ37160845-7AD22F21-5984-444E-982D-5A9B7FDD9E08Q37304217-79BC49EA-D7B2-4B2C-8DDB-65E40CD6E3B6Q37500666-65B38D92-3130-4849-9960-68EA9835EF97Q37528498-BCCB9943-F32F-48F7-AECC-ACCF9C2906E1Q37544819-79EDB27C-09DB-4039-9000-D83ED6A55B34Q37554055-568E04CD-CFCF-431F-A400-3A0A647AE432Q37643499-CF019961-325E-4ADA-8A79-9CB6E256DCE6Q37888751-C7A34BEB-8EEC-4087-87E1-8A922B040976Q38120763-464FBA06-F490-492D-8D27-724C60C0D839Q38284461-1DB170B4-A3E9-4F25-AFFD-E6095D581276Q38589279-9F838ECE-FDA6-4C39-BB9F-E0A6C01FBC25Q38613320-4216FD60-88ED-4C4C-9B3B-46AE09F6F337Q38916677-3E91E025-EBAA-42D1-8B7A-CB2F3BB37F5CQ39251474-A87F7958-37A4-47DB-91E6-70644FAE1B1BQ39458862-2F5780B2-73D9-4E74-BFC0-590B094493AAQ39464983-EDCFB278-5595-43D0-A0E2-C6CF8B843D13Q39684445-089640E4-8F83-4EF9-8447-EBC888C6C59AQ39701953-28D4C7CD-C053-4AFE-B6ED-99A20A1D2D36Q40441738-069F3EFF-E5FA-425C-A172-B0910E073230
P2860
FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
FKS mutations and elevated ech ...... population-based surveillance.
@en
FKS mutations and elevated ech ...... population-based surveillance.
@nl
type
label
FKS mutations and elevated ech ...... population-based surveillance.
@en
FKS mutations and elevated ech ...... population-based surveillance.
@nl
prefLabel
FKS mutations and elevated ech ...... population-based surveillance.
@en
FKS mutations and elevated ech ...... population-based surveillance.
@nl
P2093
P2860
P356
P1476
FKS mutations and elevated ech ...... population-based surveillance.
@en
P2093
Alicia J Zimbeck
Angela M Ahlquist
Lee H Harrison
Monica M Farley
Naureen Iqbal
Tom Chiller
P2860
P304
P356
10.1128/AAC.00836-10
P407
P577
2010-09-13T00:00:00Z